Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors

Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors

  • April 22, 2026

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too.

Leave A Comment

Fields (*) Mark are Required